https://www.ddregpharma.comenMedicineCopyright DDReg Pharmahttps://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/dbd53b7e46a6544968633f1d4188946d.jpghttps://www.ddregpharma.comFri, 07 Aug 2026 13:24:46 +0000DDReg PharmaDDReg Pharmafeeds@spreaker.com🎧 DDReg Knowledge Capsule Welcome to the DDReg Knowledge Capsule — your go-to podcast for concise, insightful conversations on the latest trends, innovations, and challenges in the life sciences industry. Brought to you by the experts at DDReg, this...falseepisodichttps://www.spreaker.com/episode/ai-in-regulatory-affairs-what-it-can-and-can-t-do-in-2026--73616672For more, visit our blog - https://resource.ddregpharma.com/blogs/ai-in-regulatory-affairs/]]>e2b026ed-f60a-4930-971a-d7446a08717aFri, 07 Aug 2026 11:58:53 +0000DDReg PharmaWelcome to the DDReg Knowledge Capsule. In this episode, we cut through the industry hype to examine exactly what AI can and cannot do in 2026. Learn why AI struggles with complex, judgment-dependent tasks like clinical risk-benefit assessments, novel...For more, visit our blog - https://resource.ddregpharma.com/blogs/ai-in-regulatory-affairs/]]>1328falsefullhttps://www.spreaker.com/episode/nafdac-drug-registration-nigeria-market-access-guide-2026--73282863https://resource.ddregpharma.com/blogs/nafdac-drug-registration-nigeria/]]>9e2a93bf-a361-46af-88a0-5b75ff5708c1Fri, 31 Jul 2026 12:28:18 +0000DDReg PharmaThis Podcast about Nigeria has emerged as one of Africa’s most dynamic pharmaceutical markets, but for global manufacturers, the path to entry is defined by the rigorous oversight of the National Agency for Food and Drug Administration and Control...https://resource.ddregpharma.com/blogs/nafdac-drug-registration-nigeria/]]>1283falsefullhttps://www.spreaker.com/episode/the-raas-revolution-in-pharma-2026--73145237Regulatory-as-a-Service (RaaS). We break down how this agile model provides on-demand access to global regulatory expertise and advanced technology—such as AI-powered dossiers and autonomous compliance agents—while significantly reducing fixed overhead costs. Tune in to learn how RaaS is helping firms stay "always audit-ready" in a rapidly shifting global landscape
]]>489473c0-e149-4f54-9623-902d6f089eeeFri, 24 Jul 2026 11:20:32 +0000DDReg PharmaIn this episode, we explore why pharmaceutical companies are moving away from traditional internal departments and adopting https://resource.ddregpharma.com/blogs/regulatory-as-a-service-raas/. We break down how this agile model provides on-demand...Regulatory-as-a-Service (RaaS). We break down how this agile model provides on-demand access to global regulatory expertise and advanced technology—such as AI-powered dossiers and autonomous compliance agents—while significantly reducing fixed overhead costs. Tune in to learn how RaaS is helping firms stay "always audit-ready" in a rapidly shifting global landscape
]]>1181falsefullhttps://www.spreaker.com/episode/winning-thailand-fda-priority-drug-approvals--73015307For more details - https://resource.ddregpharma.com/blogs/thailand-fda-priority-review-eligibility-timelines-accelerated-drug-approval-strategy/]]>86350bf0-57d4-4244-839b-0e460c236911Thu, 16 Jul 2026 12:39:23 +0000DDReg PharmaWelcome to the DDReg Knowledge Capsule. In this episode, we demystify the Thailand FDA Priority Review, a process that functions more as a controlled acceleration mechanism than a straightforward fast track. While many sponsors expect a simple path to...For more details - https://resource.ddregpharma.com/blogs/thailand-fda-priority-review-eligibility-timelines-accelerated-drug-approval-strategy/]]>1407falsefullhttps://www.spreaker.com/episode/egypt-eda-drug-approval-and-registration-guide--72915300Read View - https://resource.ddregpharma.com/blogs/egypt-eda-drug-approval-regulatory-framework-dossier-requirements-authorization-strategy/]]>3ca5e7bb-283f-4113-b062-d9581bc3a9c0Fri, 10 Jul 2026 12:42:29 +0000DDReg PharmaThis episode explores why Egypt is a top priority for regional expansion, boasting a pharmaceutical sector valued at approximately USD 5.9 billion.We dive into the regulatory framework established by Law No. 151 of 2019, which transitioned authority...Read View - https://resource.ddregpharma.com/blogs/egypt-eda-drug-approval-regulatory-framework-dossier-requirements-authorization-strategy/]]>1195falsefullhttps://www.spreaker.com/episode/navigating-tga-australia-drug-registration-and-compliance--72804419For more, visit our blog: https://resource.ddregpharma.com/blogs/tga-australia-drug-registration/]]>3aba2589-1181-465f-a180-d16d5f17dbabFri, 03 Jul 2026 11:19:13 +0000DDReg PharmaThis episode provides a comprehensive guide to the Therapeutic Goods Act 1989, exploring the various pathways for getting prescription medicines onto the Australian Register of Therapeutic Goods (ARTG). We dive into the differences between Standard,...For more, visit our blog: https://resource.ddregpharma.com/blogs/tga-australia-drug-registration/]]>1553falsefullhttps://www.spreaker.com/episode/global-orphan-drug-designations-building-a-cross-market-strategy--72756640For more details, visit our blog: https://resource.ddregpharma.com/blogs/orphan-drug-designation-strategy/]]>ba88ff4f-8a69-4545-b2dd-69529c4029d9Tue, 30 Jun 2026 11:07:35 +0000DDReg PharmaIn this episode of the DDReg Knowledge Capsule, we explore the strategic importance of building a comprehensive, multi-market regulatory approach for rare disease treatments. While orphan drug frameworks in the US, EU, Japan, and Australia share the...For more details, visit our blog: https://resource.ddregpharma.com/blogs/orphan-drug-designation-strategy/]]>1330falsefullhttps://www.spreaker.com/episode/sri-lanka-s-2026-medical-device-regulatory-registration--72698173https://resource.ddregpharma.com/blogs/medical-device-registration-in-sri-lanka/]]>cb94116b-57d2-4550-8a50-59fd79803cebFri, 26 Jun 2026 05:32:59 +0000DDReg PharmaIn this episode, we explore the significant transformation of the medical device landscape in Sri Lanka under the mandate of the NMRA. We break down the risk-based classification system—from low-risk Class One items like bandages to the high-risk apex...https://resource.ddregpharma.com/blogs/medical-device-registration-in-sri-lanka/]]>1271falsefullhttps://www.spreaker.com/episode/south-korea-mfds-drug-registration-2026-updates-and-approval-guide--72534419For more, visit our blog - https://resource.ddregpharma.com/blogs/mfds-drug-registration-in-south-korea/]]>e7a68bdd-29cc-496f-a5ae-f114ce2dfecfMon, 15 Jun 2026 12:18:00 +0000DDReg PharmaThis episode explores the significant 2026 updates to the Ministry of Food and Drug Safety (MFDS) drug registration process in South Korea. We dive into the relaxation of mandatory domestic clinical trials in favour of multinational Phase 3 data, the...For more, visit our blog - https://resource.ddregpharma.com/blogs/mfds-drug-registration-in-south-korea/]]>1219falsefullhttps://www.spreaker.com/episode/2026-sfda-roadmap-mastering-pharmaceutical-registration-in-saudi-arabia--72498307


]]>c8c8efec-bc67-4adf-9e68-7f2cf84dd63fFri, 12 Jun 2026 12:01:43 +0000DDReg PharmaIn this episode of the DDReg Knowledge Capsule, we explore the regulatory complexities of entering the Middle East’s largest pharmaceutical market, currently valued between $10.5 and $12.3 billion. We break down the SFDA’s comprehensive registration...


]]>1284falsefullhttps://www.spreaker.com/episode/how-to-winning-the-anvisa-drug-registration-race--72496560https://resource.ddregpharma.com/blogs/drug-registration-process-in-brazil/]]>2277a295-cbc0-436a-83e9-524e445f41b3Fri, 12 Jun 2026 08:26:17 +0000DDReg PharmaThis podcast, Episode [32], introduced with the "DDReg Knowledge capsule" greeting, provides a deep dive into the complexities of pharmaceutical registration in Brazil. It explores the central role of ANVISA (National Health Surveillance Agency) and...https://resource.ddregpharma.com/blogs/drug-registration-process-in-brazil/]]>1122falsefullhttps://www.spreaker.com/episode/the-blueprint-for-effective-pharmacovigilance-sops--72482860



]]>cce56d62-7d98-470e-8de0-4fcffc7afc20Thu, 11 Jun 2026 14:30:00 +0000DDReg PharmaWelcome to this episode of the DDReg Knowledge Capsule, Episode [31] where we explore the critical role of Standard Operating Procedures (SOPs) as the foundation of a reliable pharmacovigilance (PV) system. This discussion highlights how well-written...



]]>1477falsefullhttps://www.spreaker.com/episode/indonesia-s-pharma-market-bpom-drug-registration-decoded--72473455https://resource.ddregpharma.com/blogs/bpom-drug-registration-indonesia-market-entry-guide/]]>ce1e10c5-7436-4f16-bf0a-d45689bd6e07Thu, 11 Jun 2026 05:46:17 +0000DDReg Pharma📢 DDReg Knowledge Capsule – Episode [30]This podcast provides an in-depth analysis of Indonesia's regulatory landscape, the largest pharmaceutical market in Southeast Asia, with a population exceeding 270 million. It details the methodical and...https://resource.ddregpharma.com/blogs/bpom-drug-registration-indonesia-market-entry-guide/]]>1270falsefullhttps://www.spreaker.com/episode/the-who-global-strategy-on-digital-health-2027-framework--70624108https://resource.ddregpharma.com/blogs/gidh-who-global-strategy-digital-health-2027/]]>f7f5540e-e0ed-4256-9382-0f1c35f83961Fri, 13 Mar 2026 12:34:24 +0000DDReg Pharma📢 DDReg Knowledge Capsule – Episode [29]The shift in global healthcare as digital tools move from experimental pilots to core national infrastructure. It highlights the collaborative roles of the World Health Organisation (WHO), which defines the...https://resource.ddregpharma.com/blogs/gidh-who-global-strategy-digital-health-2027/]]>1155falsefullhttps://www.spreaker.com/episode/regulatory-impact-of-manufacturing-site-transfers--70322123https://resource.ddregpharma.com/blogs/regulatory-impact-manufacturing-site-transfers/
]]>a403357b-0b75-4a09-8ced-282658b82225Fri, 27 Feb 2026 05:30:00 +0000DDReg Pharma📢 DDReg Knowledge Capsule – Episode [28]This podcast covers the analysis of the regulatory complexities involved when relocating production facilities for pharmaceuticals, biologics, and medical devices. Moving a manufacturing site is not a simple...https://resource.ddregpharma.com/blogs/regulatory-impact-manufacturing-site-transfers/
]]>1098falsefullhttps://www.spreaker.com/episode/post-market-clinical-follow-up-regulatory-obligations-and-documentation-strategies--70172833https://resource.ddregpharma.com/blogs/post-market-clinical-follow-up-in-eu-medical-devices/]]>a81ed00b-28e0-4f26-adb4-5d6492097081Fri, 20 Feb 2026 05:33:01 +0000DDReg Pharma📢 DDReg Knowledge Capsule – Episode [27]This podcast covers Post-Market Clinical Follow-up (PMCF) under the European Union’s Medical Device Regulation (MDR). It describes how manufacturers must transition from passive monitoring to a continuous,...https://resource.ddregpharma.com/blogs/post-market-clinical-follow-up-in-eu-medical-devices/]]>1258falsefullhttps://www.spreaker.com/episode/ethnic-sensitivity-factors-in-global-drug-development--70032302https://resource.ddregpharma.com/blogs/ethnic-sensitivity-in-drug-development/]]>7bdc7e34-06c9-4b36-a872-a34395b6f991Fri, 13 Feb 2026 05:31:41 +0000DDReg Pharma📢 DDReg Knowledge Capsule – Episode [26]This podcast cover about how ethnic sensitivity influences the creation and approval of pharmaceuticals on a global scale. It highlights that biological differences, such as genetics and metabolism,...https://resource.ddregpharma.com/blogs/ethnic-sensitivity-in-drug-development/]]>996falsefullhttps://www.spreaker.com/episode/mandating-bridging-studies-under-ich-e5-regulatory-criteria--69842862https://resource.ddregpharma.com/blogs/bridging-studies-mandatory-under-ich-e5/]]>e36a6886-43b1-4572-8ef3-03451bdd773fFri, 06 Feb 2026 11:22:26 +0000DDReg Pharma📢 DDReg Knowledge Capsule – Episode [25]This podcast cover about ICH E5 guidelines mandate bridging studies when foreign clinical data cannot reliably predict a drug's safety or efficacy in a local population. Requirements depend on ethnic...https://resource.ddregpharma.com/blogs/bridging-studies-mandatory-under-ich-e5/]]>1063falsefullhttps://www.spreaker.com/episode/cultural-nuances-in-global-adverse-event-reporting--69683203https://resource.ddregpharma.com/blogs/cultural-nuances-in-adverse-event-reporting/]]>ec13c44e-ab6f-41c1-ae1c-6acb7a8b68dbFri, 30 Jan 2026 10:12:35 +0000DDReg Pharma📢 DDReg Knowledge Capsule – Episode [24]How cultural influences create significant discrepancies in adverse event reporting and patient-reported outcomes within global pharmacovigilance. It highlights that inconsistencies in safety data often stem...https://resource.ddregpharma.com/blogs/cultural-nuances-in-adverse-event-reporting/]]>1165falsefullhttps://www.spreaker.com/episode/scaling-quality-compliance-and-audits-across-global-networks--69679374https://resource.ddregpharma.com/blogs/managing-supplier-compliance-and-audits-across-global-networks/]]>b9cf7fd5-f3c7-41ce-b1b3-666f29e08d4bFri, 30 Jan 2026 05:20:51 +0000DDReg Pharma📢 DDReg Knowledge Capsule – Episode [23]importance of maintaining rigorous oversight of external vendors within the international pharmaceutical and medical device sectors. It explains that regulatory bodies hold the primary product owners directly...https://resource.ddregpharma.com/blogs/managing-supplier-compliance-and-audits-across-global-networks/]]>986falsefullhttps://www.spreaker.com/episode/clinical-trial-design-strategies-for-advanced-therapies--69467697https://resource.ddregpharma.com/blogs/clinical-trial-design-for-advanced-therapies/]]>b4e86c4e-177b-4fe7-9249-6f95cdafde86Fri, 16 Jan 2026 12:27:39 +0000DDReg Pharma📢 DDReg Knowledge Capsule – Episode [22]Designing clinical trials specifically for advanced medicinal products such as gene and cell therapies. Because these treatments possess unique biological complexities, the source emphasizes that standard drug...https://resource.ddregpharma.com/blogs/clinical-trial-design-for-advanced-therapies/]]>831falsefullhttps://www.spreaker.com/episode/advanced-fmea-in-medical-device-lifecycle-management--69368356https://resource.ddregpharma.com/blogs/fmea-in-medical-device-lifecycle-management/]]>967807d0-7203-4d08-86cf-e2551b8c92a8Fri, 09 Jan 2026 05:35:05 +0000DDReg Pharma📢 DDReg Knowledge Capsule – Episode [22] Failure Mode and Effects Analysis (FMEA) as a dynamic tool for managing medical device risks throughout their entire lifespan. Rather than treating it as a one-time paperwork requirement, the source advocates...https://resource.ddregpharma.com/blogs/fmea-in-medical-device-lifecycle-management/]]>812falsefullhttps://www.spreaker.com/episode/10-rules-for-2026-life-sciences-approvals--69324315https://resource.ddregpharma.com/blogs/llifesciences-compliance-in-2025/]]>c0271bb5-ecb6-4057-94a4-194a65f14183Tue, 06 Jan 2026 12:34:14 +0000DDReg Pharma📢 DDReg Knowledge Capsule – Episode [21] Integration of Artificial Intelligence and the establishment of digital trust. It asserts that the pervasive use of AI in functions like pharmacovigilance and R&D has led to an erosion of digital trust,...https://resource.ddregpharma.com/blogs/llifesciences-compliance-in-2025/]]>745falsefullhttps://www.spreaker.com/episode/fda-510-k-submission-process-guide-for-2026--69133416179338f7-f61c-4205-89d0-49531ddfcaf3Fri, 19 Dec 2025 13:05:05 +0000DDReg Pharma📢 DDReg Knowledge Capsule – Episode [20] Integration of Artificial Intelligence and the establishment of digital trust. It asserts that the pervasive use of AI in functions like pharmacovigilance and R&D has led to an erosion of digital trust,...701falsefullhttps://www.spreaker.com/episode/ai-auditability-the-foundation-of-digital-trust-in-pharma--68897932https://resource.ddregpharma.com/blogs/ai-auditability-in-pharma/]]>d85654d7-048f-4661-9434-22acd29523d8Fri, 05 Dec 2025 09:27:31 +0000DDReg Pharma📢 DDReg Knowledge Capsule – Episode [20]Integration of Artificial Intelligence and the establishment of digital trust. It asserts that the pervasive use of AI in functions like pharmacovigilance and R&D has led to an erosion of digital trust,...https://resource.ddregpharma.com/blogs/ai-auditability-in-pharma/]]>893falsefullhttps://www.spreaker.com/episode/the-regulatory-nexus-borderline-product-classification--68894160https://resource.ddregpharma.com/blogs/understanding-borderline-products-regulatory-classification-challenges-and-strategy/]]>a0eba96d-ea5d-466a-95fe-8d22047f8f2dFri, 05 Dec 2025 05:00:03 +0000DDReg Pharma📢 DDReg Knowledge Capsule – Episode [19]These products, which often exhibit characteristics overlapping categories like medicines, medical devices, and food supplements, present a significant challenge because misclassification carries substantial...https://resource.ddregpharma.com/blogs/understanding-borderline-products-regulatory-classification-challenges-and-strategy/]]>906falsefullhttps://www.spreaker.com/episode/hong-kong-s-mandatory-medical-device-registration-transition--68719983https://resource.ddregpharma.com/blogs/mandatory-medical-device-registration-in-hong-kong/]]>3428401a-9a3f-4be9-99d3-fca927dfb9f0Fri, 21 Nov 2025 11:25:14 +0000DDReg Pharma📢 DDReg Knowledge Capsule – Episode [18]Hong Kong is transitioning from the Medical Device Administrative Control System (MDACS), a voluntary listing mechanism, to a new statutory mandatory registration system. This significant shift is driven by the...https://resource.ddregpharma.com/blogs/mandatory-medical-device-registration-in-hong-kong/]]>891falsefullhttps://www.spreaker.com/episode/ectd-4-0-redefining-regulatory-submission-strategy-and-digitization--68719997657a3ce9-ac02-45d5-99b1-2df584232c21Fri, 21 Nov 2025 05:30:32 +0000DDReg Pharma📢 DDReg Knowledge Capsule – Episode [17]The significant global shift toward eCTD 4.0 for regulatory dossier submissions in the pharmaceutical industry. This new standard moves regulatory management from static files to a data-driven connected...372falsefullhttps://www.spreaker.com/episode/the-essential-role-of-the-eu-qppv-in-pharmacovigilance--68719984QPPV services is a legally mandated strategic leader for every Marketing Authorisation Holder, continuously ensuring the safety and benefit-risk profile of marketed medicines in line with EU pharmacovigilance (PV) legislation. The article details the QPPV’s five core responsibilities, including oversight of the PV system, maintenance of the Pharmacovigilance System Master File (PSMF), and acting as the primary regulatory interface for safety matters.
]]>da40dddd-b4a4-4473-96f5-ed7220e1b408Mon, 10 Nov 2025 12:42:35 +0000DDReg Pharma📢 DDReg Knowledge Capsule – Episode [16]Role of the Qualified Person Responsible for Pharmacovigilance (QPPV) in the European Union (EU). It clarifies that the https://www.ddregpharma.com/solutions/pharmacovigilance/qppv-services is a legally mandated...QPPV services is a legally mandated strategic leader for every Marketing Authorisation Holder, continuously ensuring the safety and benefit-risk profile of marketed medicines in line with EU pharmacovigilance (PV) legislation. The article details the QPPV’s five core responsibilities, including oversight of the PV system, maintenance of the Pharmacovigilance System Master File (PSMF), and acting as the primary regulatory interface for safety matters.
]]>1127falsefullhttps://www.spreaker.com/episode/combination-products-global-regulatory-convergence-and-complexity--68719990https://resource.ddregpharma.com/blogs/combination-products-in-2025-regulatory-convergence-or-compounding-complexity-2/]]>c1883d28-ca5d-48db-9f39-23f2c394a94bFri, 07 Nov 2025 08:36:50 +0000DDReg Pharma📢 DDReg Knowledge Capsule – Episode [15]The regulatory landscape for combination products in 2025, defining them as items where drugs, devices, or biologics combine for a single therapeutic effect, such as insulin pens. It highlights the rapid growth...https://resource.ddregpharma.com/blogs/combination-products-in-2025-regulatory-convergence-or-compounding-complexity-2/]]>1083falsefullhttps://www.spreaker.com/episode/ai-reshaping-pharmacovigilance-signal-detection-and-case-management--68719985https://resource.ddregpharma.com/blogs/how-ai-driven-signal-detection-is-reshaping-pharmacovigilance-case-management/]]>b058ef2b-75de-41ad-8a78-cb6d37a8222aFri, 24 Oct 2025 13:13:08 +0000DDReg Pharma📢 DDReg Knowledge Capsule – Episode [14]How Artificial Intelligence (AI) is fundamentally transforming the field of pharmacovigilance (PV), specifically in case management and signal detection. It explains that AI technologies, such as Natural...https://resource.ddregpharma.com/blogs/how-ai-driven-signal-detection-is-reshaping-pharmacovigilance-case-management/]]>778falsefullhttps://www.spreaker.com/episode/pharmacovigilance-for-cell-and-gene-therapies--68719998https://resource.ddregpharma.com/blogs/pharmacovigilance-in-cell-gene-therapy-safety-challenges-beyond-the-science/]]>3a7c891d-98de-4fda-a973-85deda600b1aThu, 16 Oct 2025 06:22:14 +0000DDReg Pharma📢 DDReg Knowledge Capsule – Episode [13]This Podcast explains that because CGTs are transformative but complex, specialised pharmacovigilance (PV) is essential throughout the entire product lifecycle, from preclinical evaluation to long-term follow-up...https://resource.ddregpharma.com/blogs/pharmacovigilance-in-cell-gene-therapy-safety-challenges-beyond-the-science/]]>843falsefullhttps://www.spreaker.com/episode/ai-utility-in-regulatory-intelligence-beyond-the-hype--68719986Artificial Intelligence (AI) in Regulatory Intelligence (RI), seeking to differentiate the genuine utility of the technology from industry hype. It defines RI as the process of evaluating regulatory data to support strategic decision-making and compliance, particularly within sectors like pharmaceuticals and medical devices. The text contrasts oversimplified expectations, such as AI replacing regulatory professionals or fully automating compliance, with practical applications like automated document processing using NLP models, trend detection, and multilingual translation. ]]>da168cb3-73d4-42c2-93e6-26a43b87c6faThu, 09 Oct 2025 05:31:59 +0000DDReg Pharma📢 DDReg Knowledge Capsule – Episode [12]Discusses the application of https://resource.ddregpharma.com/blogs/ai-in-regulatory-intelligence-separating-real-utility-from-industry-buzz/(RI), seeking to differentiate the genuine utility of the technology...Artificial Intelligence (AI) in Regulatory Intelligence (RI), seeking to differentiate the genuine utility of the technology from industry hype. It defines RI as the process of evaluating regulatory data to support strategic decision-making and compliance, particularly within sectors like pharmaceuticals and medical devices. The text contrasts oversimplified expectations, such as AI replacing regulatory professionals or fully automating compliance, with practical applications like automated document processing using NLP models, trend detection, and multilingual translation. ]]>1013falsefullhttps://www.spreaker.com/episode/mrna-technology-expansion-beyond-vaccines--68719988mRNA visibility, its scope now includes cancer immunotherapies, treatments for genetic and metabolic disorders, and regenerative medicine, with the global market projected for significant growth. The text also outlines both the key benefits of mRNA, such as speed and versatility, and the inherent challenges, including stability issues, delivery complexity, and high manufacturing costs. Finally, the document details the regulatory landscape for mRNA therapeutics, highlighting frameworks from the U.S. FDA, the EMA, and the WHO, and asserts DDReg’s role in helping companies navigate these complex approval pathways.]]>b6e0d1b0-6f40-44ef-870b-deb3fe679260Wed, 01 Oct 2025 12:13:09 +0000DDReg Pharma📢 DDReg Knowledge Capsule – Episode [11]while the COVID-19 pandemic accelerated https://resource.ddregpharma.com/blogs/how-mrna-technology-is-expanding-beyond-vaccines/, its scope now includes cancer immunotherapies, treatments for genetic and...mRNA visibility, its scope now includes cancer immunotherapies, treatments for genetic and metabolic disorders, and regenerative medicine, with the global market projected for significant growth. The text also outlines both the key benefits of mRNA, such as speed and versatility, and the inherent challenges, including stability issues, delivery complexity, and high manufacturing costs. Finally, the document details the regulatory landscape for mRNA therapeutics, highlighting frameworks from the U.S. FDA, the EMA, and the WHO, and asserts DDReg’s role in helping companies navigate these complex approval pathways.]]>763falsefullhttps://www.spreaker.com/episode/uae-pharma-gateway-a-guide-to-uae-pharmaceutical-registration--68719994drug product registration process in UAE. We explore the roles of the two key regulatory authorities: the Ministry of Health and Prevention (MOHAP), which handles facility licensing and product importation, and the Emirates Drug Establishment (EDE), which oversees everything from clinical testing to drug approvals.]]>f7fa245f-3736-4ef0-ae06-17e182641c38Tue, 30 Sep 2025 12:58:23 +0000DDReg PharmaThe United Arab Emirates is one of the Middle East's fastest-growing pharmaceutical markets, offering a strategic gateway for global manufacturers But entering this lucrative market requires navigating a complex regulatory landscape.In this episode,...drug product registration process in UAE. We explore the roles of the two key regulatory authorities: the Ministry of Health and Prevention (MOHAP), which handles facility licensing and product importation, and the Emirates Drug Establishment (EDE), which oversees everything from clinical testing to drug approvals.]]>903falsefullhttps://www.spreaker.com/episode/pharmacovigilance-in-new-zealand--68719992pharmacovigilance in New Zealand, highlighting the regulatory framework overseen by Medsafe under the Medicines Act 1981. It explains that the country participates in the WHO International Drug Monitoring Programme and uses systems like the Suspected Medicine Adverse Reaction Search (SMARS) database to gather post-market safety information. The text outlines the responsibilities of pharmaceutical sponsors, including appointing a contact person and adhering to strict timelines—such as reporting serious adverse reactions within 15 days and urgent safety issues within 72 hours—as mandated by updated guidelines.]]>1f24f098-f6ce-4299-b1e8-20daae1375dbThu, 25 Sep 2025 12:58:33 +0000DDReg Pharma📢 DDReg Knowledge Capsule – Episode [9]Overview of https://resource.ddregpharma.com/blogs/pharmacovigilance-in-new-zealand/, highlighting the regulatory framework overseen by Medsafe under the Medicines Act 1981. It explains that the country...pharmacovigilance in New Zealand, highlighting the regulatory framework overseen by Medsafe under the Medicines Act 1981. It explains that the country participates in the WHO International Drug Monitoring Programme and uses systems like the Suspected Medicine Adverse Reaction Search (SMARS) database to gather post-market safety information. The text outlines the responsibilities of pharmaceutical sponsors, including appointing a contact person and adhering to strict timelines—such as reporting serious adverse reactions within 15 days and urgent safety issues within 72 hours—as mandated by updated guidelines.]]>899falsefullhttps://www.spreaker.com/episode/pv-inspection-guide-for-your-auditing-mastery-in-fda-and-ema--68720005pharmacovigilance (PV) inspections preparedness, conducted globally by regulatory bodies to ensure compliance among marketing authorization holders. These inspections, which can be announced or unannounced, verify that systems, facilities, and processes adhere to PV requirements and aim to identify non-compliance that could potentially harm patients. The article outlines various types of PV inspections, common areas covered, and the specific agendas of key regulatory authorities, including the FDA, EMA, and MHRA.]]>51685f00-4aa5-4b08-be60-ebbd46e4216bThu, 25 Sep 2025 07:40:02 +0000DDReg Pharma📢 DDReg Knowledge Capsule – Episode [9]https://resource.ddregpharma.com/blogs/preparedness-for-inspections/, conducted globally by regulatory bodies to ensure compliance among marketing authorization holders. These inspections, which can be announced...pharmacovigilance (PV) inspections preparedness, conducted globally by regulatory bodies to ensure compliance among marketing authorization holders. These inspections, which can be announced or unannounced, verify that systems, facilities, and processes adhere to PV requirements and aim to identify non-compliance that could potentially harm patients. The article outlines various types of PV inspections, common areas covered, and the specific agendas of key regulatory authorities, including the FDA, EMA, and MHRA.]]>802falsefullhttps://www.spreaker.com/episode/mexico-drug-registration-process-via-cofepris--68719991drug registration process in Mexico, highlighting its importance as the second-largest pharmaceutical market in Latin America. The core of the process is overseen by the Federal Commission for the Protection against Sanitary Risks (COFEPRIS), which categorises medicines into distinct regulatory pathways, such as New Chemical Entities and generics, each with different timelines and requirements. Key strategic elements for successful market entry include submitting all required documents in Spanish, appointing a mandatory local legal representative ("responsable sanitario"), and adhering to Good Manufacturing Practice (GMP) standards.]]>0a10d876-e2fe-4795-be53-4ec84042543fWed, 24 Sep 2025 12:54:12 +0000DDReg Pharma📢 DDReg Knowledge Capsule – Episode [8]In-depth guide to the https://resource.ddregpharma.com/blogs/understanding-the-drug-registration-process-in-mexico/, highlighting its importance as the second-largest pharmaceutical market in Latin America. The...drug registration process in Mexico, highlighting its importance as the second-largest pharmaceutical market in Latin America. The core of the process is overseen by the Federal Commission for the Protection against Sanitary Risks (COFEPRIS), which categorises medicines into distinct regulatory pathways, such as New Chemical Entities and generics, each with different timelines and requirements. Key strategic elements for successful market entry include submitting all required documents in Spanish, appointing a mandatory local legal representative ("responsable sanitario"), and adhering to Good Manufacturing Practice (GMP) standards.]]>774falsefullhttps://www.spreaker.com/episode/new-drug-approval-roadmap-according-to-cdsco--68720000 register their new drug product in the Indian market.]]>f8e7a41c-3589-4568-a063-18f222a50963Wed, 24 Sep 2025 05:57:17 +0000DDReg Pharma📢 DDReg Knowledge Capsule – Episode [8]In this podcast, we cover the steps and points that any global and local entity should follow when planning tohttps://resource.ddregpharma.com/blogs/step-by-step-guide-to-new-drug-registration-and-approval-in-india/. register their new drug product in the Indian market.]]>728falsefullhttps://www.spreaker.com/episode/pharma-packaging-revolution-in-eu-ppwr--68719996⁠⁠⁠ In-depth analysis of the European Union’s Packaging and Packaging Waste Regulation (EU PPWR), officially designated as Regulation (EU) 2024/1781, which replaces a previous directive to mandate stricter sustainability standards across the EU. This new regulation, which entered into force in February 2025, aims to prevent waste, ensure all packaging is recyclable by 2030, and harmonize rules across member states. A significant portion of the text focuses on how the PPWR specifically impacts the pharmaceutical industry, noting that while contact-sensitive medicinal packaging receives temporary exemptions from recycled content and immediate recyclability targets due to safety concerns, outer and secondary packaging must comply with rules concerning recyclability and maximum empty space.]]>e4cd7694-5ca3-4e24-802c-98926752173bTue, 23 Sep 2025 13:07:01 +0000DDReg Pharma📢 DDReg Knowledge Capsule – Episode [7]https://resource.ddregpharma.com/blogs/strategic-pharmacovigilance-checklist-for-biosimilar-safety-in-2025/ In-depth analysis of the...⁠⁠⁠ In-depth analysis of the European Union’s Packaging and Packaging Waste Regulation (EU PPWR), officially designated as Regulation (EU) 2024/1781, which replaces a previous directive to mandate stricter sustainability standards across the EU. This new regulation, which entered into force in February 2025, aims to prevent waste, ensure all packaging is recyclable by 2030, and harmonize rules across member states. A significant portion of the text focuses on how the PPWR specifically impacts the pharmaceutical industry, noting that while contact-sensitive medicinal packaging receives temporary exemptions from recycled content and immediate recyclability targets due to safety concerns, outer and secondary packaging must comply with rules concerning recyclability and maximum empty space.]]>958falsefullhttps://www.spreaker.com/episode/translational-biology-accelerating-tomorrow-s-therapies--68719995⁠Introduces the concept of Translational Biology and explains how this field is accelerating the development of new therapies by creating a continuous feedback loop between laboratory discovery and patient care. The article outlines the multi-stage Translational Biology Pipeline (T0 to T4), which moves findings from basic research through clinical trials and into public health practice. It also identifies several cutting-edge tools and techniques used in this research, such as proteomics, biomarker analysis, and computational modeling, alongside the primary challenges related to funding and regulatory complexity. ]]>e613de45-da4e-4e27-ac82-f03472247000Tue, 23 Sep 2025 05:24:46 +0000DDReg Pharma📢 DDReg Knowledge Capsule – Episode [6]https://resource.ddregpharma.com/blogs/strategic-pharmacovigilance-checklist-for-biosimilar-safety-in-2025/Introduces the concept...⁠Introduces the concept of Translational Biology and explains how this field is accelerating the development of new therapies by creating a continuous feedback loop between laboratory discovery and patient care. The article outlines the multi-stage Translational Biology Pipeline (T0 to T4), which moves findings from basic research through clinical trials and into public health practice. It also identifies several cutting-edge tools and techniques used in this research, such as proteomics, biomarker analysis, and computational modeling, alongside the primary challenges related to funding and regulatory complexity. ]]>950falsefullhttps://www.spreaker.com/episode/biosimilar-safety-in-2025-your-strategic-pharmacovigilance-checklist--68720003Strategic Pharmacovigilance Checklist for Biosimilar Safety in 2025," which offers guidance on managing the increasing complexities of biosimilar safety. The article explains that the biosimilar market is rapidly expanding, necessitating robust pharmacovigilance (PV) to ensure patient safety and mitigate risks. It presents a comprehensive checklist covering key areas such as creating unique Risk Management Plans (RMPs), prioritizing immunogenicity oversight, ensuring detailed traceability and product identification, and employing advanced signal detection techniques using AI/ML tools.]]>1337e331-6f5d-4a2b-b0d3-60949663eeb2Mon, 22 Sep 2025 12:03:10 +0000DDReg Pharma📢 DDReg Knowledge Capsule – Episode [6]https://resource.ddregpharma.com/blogs/strategic-pharmacovigilance-checklist-for-biosimilar-safety-in-2025/," which offers guidance on managing the increasing complexities of biosimilar safety. The article...Strategic Pharmacovigilance Checklist for Biosimilar Safety in 2025," which offers guidance on managing the increasing complexities of biosimilar safety. The article explains that the biosimilar market is rapidly expanding, necessitating robust pharmacovigilance (PV) to ensure patient safety and mitigate risks. It presents a comprehensive checklist covering key areas such as creating unique Risk Management Plans (RMPs), prioritizing immunogenicity oversight, ensuring detailed traceability and product identification, and employing advanced signal detection techniques using AI/ML tools.]]>1139falsefullhttps://www.spreaker.com/episode/china-pharma-market-innovation-regulation-and-global-impact--68720009308c5e51-99a6-45a7-98f7-de520a8dd90dFri, 19 Sep 2025 05:19:38 +0000DDReg Pharma📢 DDReg Knowledge Capsule – Episode [5]Overview of the drug approval process in the Chinese pharmaceutical market, highlighting its significance as the world's second-largest. It details the types of drugs approved, including innovative medicines,...863falsefullhttps://www.spreaker.com/episode/staying-vigilant-when-the-patient-volume-is-low--68719993https://resource.ddregpharma.com/blogs/signal-detection-in-low-volume-markets-how-smart-pv-teams-stay-ahead/]]>f99fe1c9-454f-47b1-86f2-96f955a56985Thu, 18 Sep 2025 10:35:09 +0000DDReg Pharma📢 DDReg Knowledge Capsule – Episode [5]Low data doesn’t mean low risk. In this episode, we unpack how PV teams detect signals in low-volume markets, using smarter tools, sharper strategies, and local expertise to keep drug safety ahead of the curve....https://resource.ddregpharma.com/blogs/signal-detection-in-low-volume-markets-how-smart-pv-teams-stay-ahead/]]>796falsefullhttps://www.spreaker.com/episode/medical-device-cybersecurity--68720004cybersecurity in connected medical devices, highlighting the critical balance between technological advancement and patient safety. It discusses the evolving landscape of cyber threats and the regulatory frameworks put in place by bodies like the FDA and the Department of Health and Human Services to address these risks.]]>1e9598e3-6bb9-4c3d-bf1d-4e2c000d92f5Fri, 22 Aug 2025 10:24:25 +0000DDReg Pharma📢 DDReg Knowledge Capsule – Episode [4]This DDReg Knowledge Capsule focuses on https://resource.ddregpharma.com/blogs/cybersecurity-in-connected-medical-devices-compliance-and-risk-mitigation/, highlighting the critical balance between technological...cybersecurity in connected medical devices, highlighting the critical balance between technological advancement and patient safety. It discusses the evolving landscape of cyber threats and the regulatory frameworks put in place by bodies like the FDA and the Department of Health and Human Services to address these risks.]]>737falsefullhttps://www.spreaker.com/episode/how-on-the-spot-testing-brings-care-closer--68720001point-of-care diagnostics (POC) as a rapidly expanding sector within the in-vitro diagnostics industry. It explains that POC devices facilitate quick medical testing near the patient, leading to faster diagnoses and improved outcomes, particularly in situations where resources are limited. ]]>f0dc0f65-a1a9-4fa7-a963-57724533c001Thu, 14 Aug 2025 13:00:30 +0000DDReg Pharma📢 DDReg Knowledge Capsule – Episode [3]In this episode of the DDReg Knowledge Capsule,introduce https://resource.ddregpharma.com/blogs/point-of-care-diagnostics-making-healthcare-more-accessible/ as a rapidly expanding sector within the in-vitro...point-of-care diagnostics (POC) as a rapidly expanding sector within the in-vitro diagnostics industry. It explains that POC devices facilitate quick medical testing near the patient, leading to faster diagnoses and improved outcomes, particularly in situations where resources are limited. ]]>927falsefullhttps://www.spreaker.com/episode/how-apps-are-changing-the-way-we-manage-chronic-illness--68720007Digital Therapeutics (DTx), highlighting their role in transforming chronic disease management. It details how DTx, which are clinically validated, software-driven interventions, empower patients through personalised, data-driven care, evidence-based behaviour change, and 24/7 accessibility. 📍Stay informed. Stay compliant. Stay ahead.]]>2240a2ad-682a-404c-9454-82146adda7baMon, 11 Aug 2025 12:00:33 +0000DDReg Pharma📢 DDReg Knowledge Capsule – Episode [2]In this episode of the DDReg Knowledge Capsule, we dive into https://resource.ddregpharma.com/blogs/digital-therapeutics-empowering-patients-to-take-charge-of-chronic-conditions/ (DTx), highlighting their role in...Digital Therapeutics (DTx), highlighting their role in transforming chronic disease management. It details how DTx, which are clinically validated, software-driven interventions, empower patients through personalised, data-driven care, evidence-based behaviour change, and 24/7 accessibility. 📍Stay informed. Stay compliant. Stay ahead.]]>960falsefullhttps://www.spreaker.com/episode/is-your-phone-app-a-medical-device--68720008Software as a Medical Device (SaMD) — a transformative area in digital health that's reshaping patient care and healthcare delivery.Join us as we explore:
🔹 What qualifies as SaMD under global regulatory frameworks
🔹 Key regulatory guidelines from the FDA, EU MDR, and IMDRF
🔹 Challenges in compliance, risk classification, and cybersecurity
🔹 Real-world examples of SaMD in diagnostics, monitoring, and therapeutics
🔹 How manufacturers can navigate regulatory pathways to ensure safety and efficacyWhether you're a MedTech innovator, regulatory professional, or healthcare stakeholder, this episode offers essential insights into how software is becoming a standalone therapeutic and diagnostic tool.📍Stay informed. Stay compliant. Stay ahead.]]>5bcc9355-aa69-49be-a339-b7fdb300165bTue, 05 Aug 2025 10:07:38 +0000DDReg Pharma📢 DDReg Knowledge Capsule – Episode [1]In this episode of the DDReg Knowledge Capsule, we dive into the evolving landscape of https://resource.ddregpharma.com/blogs/understanding-software-as-a-medical-device/ (SaMD) — a transformative area in digital...Software as a Medical Device (SaMD) — a transformative area in digital health that's reshaping patient care and healthcare delivery.Join us as we explore:
🔹 What qualifies as SaMD under global regulatory frameworks
🔹 Key regulatory guidelines from the FDA, EU MDR, and IMDRF
🔹 Challenges in compliance, risk classification, and cybersecurity
🔹 Real-world examples of SaMD in diagnostics, monitoring, and therapeutics
🔹 How manufacturers can navigate regulatory pathways to ensure safety and efficacyWhether you're a MedTech innovator, regulatory professional, or healthcare stakeholder, this episode offers essential insights into how software is becoming a standalone therapeutic and diagnostic tool.📍Stay informed. Stay compliant. Stay ahead.]]>706falsefull